A nucleic acid composition, a kit and its application for detecting human bocavirus circular genome

By designing specific primers and probes and combining them with real-time quantitative PCR technology, the problem of the inability to efficiently detect the HBoV circular genome in existing technologies has been solved, achieving rapid and accurate detection results and supporting timely intervention and treatment of the disease.

CN118668014BActive Publication Date: 2024-11-15CAPITAL INST OF PEDIATRICS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411048344.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-15
Estimated Expiration
2044-08-01

AI Technical Summary

Technical Problem

Current technologies cannot efficiently and specifically detect the circular genome of human bocavirus (HBoV), making it difficult to accurately determine its presence in samples, which affects disease diagnosis and treatment.

Method used

Specific primers and probes were designed and combined with real-time quantitative PCR technology to rapidly and accurately detect the HBoV circular genome. By adjusting the threshold and endogenous internal control, quantitative detection of the HBoV circular genome was achieved.

Benefits of technology

This enables rapid and accurate detection of the HBoV circular genome, allowing for a more precise understanding of infection status and supporting timely intervention and treatment.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to a nucleic acid composition, a kit and an application thereof for detecting a human bocavirus circular genome. The nucleic acid composition and the kit of the present invention can efficiently and accurately perform quantitative detection on the circular genome of human bocavirus (hereinafter referred to as HBoV), so as to quickly and accurately determine whether a sample contains the HBoV circular genome and determine its specific content level; when applied clinically, the infection status and information of HBoV can be more accurately known, so as to timely intervene and treat patients.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of virus detection, and in particular to a nucleic acid composition, a kit and applications thereof for detecting a human bocavirus circular genome. Background Art

[0002] Parvoviridae is one of the smallest DNA viruses known to infect mammalian cells. It is divided into two subfamilies, Parvovirinae and Densovirinae, which infect vertebrate and invertebrate cells, respectively. At present, the subfamilies of vertebrate viruses are divided into Protoparvovirus, Erythoparvovirus, Bocaparvovirus, Aveparvovirus, Copiparvovirus, Tetraparvovirus, and Amdovirus according to the number of open reading frames, transcriptional location, autonomous or with the help of helper viruses, sequence homology and other factors.

[0003] Human bocavirus (HBoV) was discovered in 2005 and belongs to the genus Bocavirus in the family Parvoviridae and subfamily Parvovirinae. At that time, it was identified as a lower respiratory tract infection in children, so as part of the "Virus Discovery Program", this respiratory virus is now classified as HBoV genotype 1, and related viruses, namely HBoV genotypes 2 to 4, were subsequently detected in stool samples.

[0004] HBoV type 1 is mainly found in respiratory secretions. Although it can be detected in every season, similar to other respiratory infections, primary infection mainly occurs in the winter and spring months. Serological studies using HBoV type 1 as an antigen have found that the vast majority of people have been infected before the age of 6. HBoV type 1 is mainly transmitted through the respiratory tract and is associated with respiratory infections (especially asthma). The NS1 gene is relatively conservative. HBoV has a high rate of co-infection with other respiratory viruses, and there is no significant difference in clinical features between HBoV infection alone and combined with other respiratory virus infections. HBoV belongs to the genus Bocavirus in the subfamily Parvovirinae, along with bovine parvovirus and canine parvovirus, and can cause acute respiratory infections in children.

[0005] Studies have shown that the genome of HBoV is single-stranded negative-strand DNA (ssDNA), and both ends of the genome contain terminal repeat sequences required to initiate genome replication, also known as hairpin structures. The left-end hairpin structure is LEH, and the right-end hairpin structure is REH. In 2011, researchers detected the circular genome of HBoV1 in specimens from children with respiratory tract infections, that is, the presence of a head-to-tail connection structure. Subsequently, circular genomes were detected in all genotypes of HBoV. It is known that the replication mechanism of Parvoviridae viruses is mainly a rolling hairpin replication mechanism that relies on the hairpin structure at both ends of the genome. This mechanism produces a head-to-head or tail-to-tail connection structure, but no head-to-head or tail-to-tail connection structure can be detected in HBoV. At the same time, the detection of the head-to-tail connection structure points to another replication mechanism - the rolling circle replication mechanism, and the rolling hairpin replication mechanism is a variant of this mechanism. Limited by the lack of susceptible cell lines and susceptible animal models, people still lack understanding of the replication mechanism of HBoV, and it is difficult to identify whether HBoV is actively infected or not from the replication intermediates. Existing studies have shown that the integrity of the entire genome of the human bocavirus circular genome, including the head and tail sequences, is very necessary for the HBoV replication process; and in the detection of clinical samples, the positive circular genome is significantly correlated with the positive HBoV antigen, so the qualitative or quantitative detection of the human bocavirus circular genome in clinical specimens is of great significance.

[0006] CN101550452B discloses a real-time fluorescence PCR detection kit, and in particular relates to a kit for detecting human bocavirus using real-time fluorescence PCR technology. The kit is simple to operate, short in time, highly sensitive, and highly specific, and can be used for qualitative or quantitative detection of human bocavirus in various types of specimens, and is used in multiple fields such as early diagnosis and epidemiological research. However, the amplification primers of the kit are only for the linear genome sequence of human bocavirus, and it is impossible to qualitatively or quantitatively study the possible circular genome, and currently only the positive or negative of the circular genome can be detected by nested PCR amplification and Sanger sequencing, which is time-consuming and laborious.

[0007] Real-time fluorescence quantitative polymerase chain reaction technology (RT-PCR) is achieved by starting point quantification and real-time monitoring of cumulative fluorescence intensity by a fluorescence detection system. It has the advantages of high sensitivity, strong specificity, good linear relationship, and simple operation. It has been widely used in rapid detection, quantitative analysis, early diagnosis, and genotyping of human and animal diseases, but false negatives are prone to occur during application.

[0008] Currently, there is an urgent need for a detection system that can efficiently and specifically detect the human bocavirus circular genome. Summary of the invention

[0009] Purpose of the Invention

[0010] In view of the above problems or needs existing in the prior art, the object of the present invention is to provide a nucleic acid composition, a kit and applications thereof for detecting the human bocavirus circular genome.

[0011] The nucleic acid composition and kit provided by the present invention can quickly and accurately perform quantitative detection on the circular genome of human bocavirus (hereinafter referred to as HBoV), so as to quickly and accurately understand the presence or absence of the HBoV circular genome in the sample; when applied clinically, the infection status and information of HBoV can be more accurately known, so as to timely intervene and treat the patient.

[0012] Solution

[0013] In order to achieve the above object, the present invention provides the following technical solutions.

[0014] In a first aspect, the present invention provides a nucleic acid composition for detecting a human bocavirus circular genome, the nucleic acid composition comprising:

[0015] A primer pair for specifically amplifying the human bocavirus circular genome, the primer pair comprising: an upstream primer HBoV-CF having a nucleotide sequence as shown in SEQ ID NO:1, and a downstream primer HBoV-CR having a nucleotide sequence as shown in SEQ ID NO:2.

[0016] In a feasible embodiment, the nucleic acid composition further comprises:

[0017] A probe HBoV-CP for specifically detecting the human bocavirus circular genome; the nucleotide sequence of the probe HBoV-CP is shown in SEQ ID NO:3.

[0018] In a feasible embodiment, the 5' end of the probe HBoV-CP is labeled with a fluorescent reporter group, and the 3' end thereof is labeled with a fluorescent quencher group.

[0019] Preferably, the fluorescent reporter group is selected from: FAM, Cy5, VIC, JOE, TET, HEX, Cy3 and ROX; further preferably, the fluorescent reporter group is selected from: FAM, Cy5, VIC and ROX;

[0020] Preferably, the fluorescence quenching group is selected from: TAMRA, BHQ1 and BHQ2; further preferably, the fluorescence quenching group is selected from: BHQ1 and BHQ2.

[0021] In a possible embodiment, the human bocavirus is human bocavirus type 1.

[0022] In a feasible embodiment, the nucleic acid composition further comprises a detection system for detecting an internal reference gene.

[0023] Preferably, the internal reference gene is a ribonuclease P gene, and the detection system for detecting the ribonuclease P gene includes:

[0024] The upstream primer RNP-F having a nucleotide sequence as shown in SEQ ID NO:4;

[0025] A downstream primer RNP-R having a nucleotide sequence as shown in SEQ ID NO:5; and,

[0026] Optionally, the nucleotide sequence of the probe RNP-P is as shown in SEQ ID NO:6.

[0027] Optionally, the 5' end of the probe RNP-P is labeled with a fluorescent reporter group, which is selected from FAM, Cy5, VIC, JOE, TET, HEX, Cy3 and ROX, preferably selected from FAM, Cy5, VIC and ROX, and is different from the fluorescent reporter group at the 5' end of the probe HBoV-CP; and the 3' end of the probe RNP-P is labeled with a fluorescent quencher group, which is selected from TAMRA, BHQ1 and BHQ2, preferably selected from BHQ1 and BHQ2.

[0028] In a second aspect, the present invention provides use of the nucleic acid composition described in the first aspect above in preparing a kit for detecting human bocavirus.

[0029] In a possible embodiment, the human bocavirus is human bocavirus type 1.

[0030] In a feasible embodiment, the kit is a real-time fluorescence quantitative PCR kit, which includes reagents required for real-time fluorescence quantitative PCR detection.

[0031] In a feasible embodiment, the kit also includes anti-contamination measures such as dUTP / UNG to avoid false positive results.

[0032] In a third aspect, the present invention provides a kit for detecting human bocavirus, comprising the nucleic acid composition as described in the first aspect above.

[0033] In a possible embodiment, the human bocavirus is human bocavirus type 1.

[0034] In a feasible embodiment, the kit is a real-time fluorescence quantitative PCR kit, which includes reagents required for real-time fluorescence quantitative PCR detection.

[0035] In a feasible embodiment, the kit also includes anti-contamination measures such as dUTP / UNG to avoid false positive results.

[0036] In a fourth aspect, the present invention provides a method for detecting human bocavirus for non-disease diagnosis purposes, characterized in that the DNA of the sample to be tested is used as a template, PCR amplification is performed using the nucleic acid composition described in the first aspect or the kit described in the third aspect, preferably real-time fluorescence quantitative PCR amplification is performed, and whether the sample to be tested contains the human bocavirus circular genome is determined based on the amplification curve.

[0037] In a feasible embodiment, the sample to be tested includes but is not limited to a throat swab, a nasal swab, a nasopharyngeal swab, a sputum or a bronchoalveolar lavage fluid sample.

[0038] In a possible embodiment, the method comprises:

[0039] (1) Establish a dual real-time fluorescence PCR detection system and perform real-time fluorescence quantitative PCR;

[0040] For example, a 20 μL PCR reaction system is configured as follows:

[0041] DNA template 5 μL;

[0042] Hot Start DNA Polymerase (5U / μL) 0.2μL;

[0043] 10× PCR buffer 2 μL;

[0044] UNG (2U / μL) 0.1μL;

[0045] dN(U)TP (25 mM) 0.16 μL;

[0046] MgCl2 (25 mM) 2.4 μL;

[0047] 10× primer-probe mixture 2 μL;

[0048] Add ultrapure water to 20 μL.

[0049] Preferably, UNG is UDG enzyme or UTG enzyme;

[0050] Preferably, the primer-probe mixture comprises: a primer pair HBoV-CF and HBoV-CR and a probe HBoV-CP for amplifying and detecting the human bocavirus circular genome, and a primer pair RNP-F and RNP-R and a probe RNP-P for amplifying and detecting the ribonuclease P gene;

[0051] Preferably, in the primer-probe mixture, the molar concentration of each primer and its corresponding probe is approximately equal, the total concentration of all primers is about 6-12 μM, and the total concentration of all probes is about 3-6 μM;

[0052] The PCR reaction conditions are as follows:

[0053] 50℃ 2min; 94℃ 5min; 94℃ 5s, 60℃ 30s, cycle 45 times.

[0054] (2) Determination of real-time fluorescence quantitative PCR results;

[0055] The methods for determining the results of real-time fluorescence quantitative PCR include:

[0056] 1) Adjust the threshold: The instrument automatically adjusts the judgment threshold according to the background value of the first 3-15 cycles of reaction;

[0057] 2) Quality control: endogenous internal reference control is established, otherwise the experiment is considered invalid;

[0058] 3) Judgment and interpretation of fluorescence detection channels: a) If the sample has S-type amplification and the CT value is less than 40, the sample is judged to be positive; b) If the sample has no obvious S-type amplification curve but a CT value is reported, it is judged to be non-specific amplification; it may be a non-specific fluorescence signal released by probe degradation.

[0059] Determination and quantitative detection of positive results of HBoV circular genome detection:

[0060] When the endogenous reference gene is detected positively, a positive signal appears in the fluorescence detection channel of the probe HBoV-CP, which is determined to be positive for the HBoV circular genome; at this time, the HBoV circular genome concentration can be calculated according to the standard curve.

[0061] Beneficial Effects

[0062] The present invention selects a conserved sequence at the head-tail junction of the HBoV circular genome in a specific manner, and designs specific detection primers and probes for the conserved sequence. The designed detection primers and probes can efficiently and specifically detect the HBoV circular genome through quantitative PCR, so that it can quickly and accurately determine whether the sample contains the HBoV circular genome and determine its specific content level; when applied clinically, it can more accurately know the infection status and information of HBoV, so as to intervene and treat patients in time. DETAILED DESCRIPTION

[0063] Unless explicitly stated otherwise, throughout the specification and claims, the term “comprise” or variations such as “include” or “comprising”, etc., will be understood to include the stated elements or components but not to exclude other elements or components.

[0064] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art.

[0065] In order to make the present invention more easily understood, some technical terms are specifically defined as follows. Unless otherwise clearly defined in other parts of this document, the technical terms used herein have the meanings commonly understood by ordinary technicians in the field to which the present invention belongs.

[0066] The term "about" when used in conjunction with a numerical value is meant to encompass the numerical value within a range having a lower limit that is 5% less than the specified numerical value and an upper limit that is 5% greater than the specified numerical value, including but not limited to ±5%, ±2%, ±1%, and ±0.1%, as such variations are appropriate for performing the disclosed methods.

[0067] The term "and / or" should be understood to mean any one of the optional items or a combination of any two or more of the optional items.

[0068] As used herein, the term "or" should be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" should be interpreted as inclusive, that is, including at least one of the numbers or elements in the list, but also including more than one, and optionally, additional unlisted items. Only when terms are clearly indicated to the contrary, such as "only one" or "exactly one" or when "consisting of..." is used in the claims, it will refer to only one number listed or one element of the list.

[0069] The technical solutions in the embodiments of the present invention are described clearly and completely below. The described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work are within the scope of protection of the present invention.

[0070] Unless otherwise specified, the materials, reagents, etc. used in the following examples can be obtained from commercial sources; unless otherwise specified, the examples are based on conventional experimental conditions or the conditions recommended in the manufacturer's instructions.

[0071] Example 1: Design of multiplex PCR primers and probes for HBoV1 circular genome and endogenous reference genes

[0072] The conserved sequence at the head-to-tail junction of the human bocavirus HBoV1 circular genome was selected, and the conserved sequence at the head-to-tail junction was confirmed through nested amplification of the preliminary head-to-tail sequences, TA cloning and Sanger sequencing. The conserved sequence segment was input into the primer design software for primer design, and through optimization screening, a specific amplification primer pair for the head-to-tail junction of the HBoV1 circular genome was obtained. A detection probe for the primer pair was further designed for the detection of the HBoV1 circular genome.

[0073] In addition, the multiplex PCR reaction system also used specific detection primers and probes of the endogenous reference gene, ribonuclease P (RNP) gene (see Table 1).

[0074] Therefore, in the design process of primer pairs and probes for amplification of the HBoV1 circular genome, it is necessary to fully consider the problem of co-amplification of primers and probes of different target genes in the same reaction system. Therefore, when designing primers and probes, it is necessary to consider the consistency of Tm values ​​and the homogenization of GC content, and to avoid the occurrence of hairpin structures and primer dimers as much as possible to ensure the probability of simultaneous amplification of different primer probes in the same reaction system in the later stage.

[0075] All primer probe sequences were subjected to BLAST analysis in Genbank, and primer probes with good specificity were determined as primer probe schemes for experimental verification. Single-plex PCR verification was performed on primer probes for detection of HBoV circular genome to determine the availability of primer probes, including specificity evaluation and sensitivity evaluation. Multiplex PCR was performed on all primer pairs and probes for HBoV circular genome and internal reference gene to verify the availability of all primers and probes for simultaneous amplification in the same reaction system. For primer pairs and probes that do not work, new primer pairs and probes need to be designed according to the above primer design steps to replace them. In this way, multiple screening was performed to obtain primer pairs and probes for amplification of HBoV circular genome that can be used in multiplex PCR reaction systems, as shown in Table 1 below.

[0076] Table 1. Multiplex PCR primer and probe sequence information of HBoV circular genome and internal reference gene

[0077] Target Type Primer probe sequence (5'-3') The 5' end of the probe sequence is a luminescent group, and the 3' end is a quenching group SEQ ID NO. HBoV circular genome-upstream primer HBoV-CF GAAGTGCAGCAGCTTATATAGGTTTAAT 1 HBoV circular genome-downstream primer HBoV-CR TGTTTTGTTTGCTTATGCAATCG 2 HBoV circular genome-probe HBoV-CP FAM-CTGATTGGCTATCATACGTCATTTCCTGGGA-BHQ1 3 Endogenous reference - upstream primer RNP-F AGATTTGGACCTGCGAGCG 4 Endogenous internal reference - downstream primer RNP-R GAGCGGCTGTCTCCACAAGT 5 Endogenous reference probe RNP-P ROX-TTCTGACCTGAAGGCTCTGCGCG-BHQ2 6 .

[0078] The primer pairs and probes shown in Table 1 were assembled into a kit as a representative example of the kit of the present invention (hereinafter referred to as the kit of the present invention).

[0079] Example 2: Real-time fluorescence quantitative PCR detection of HBoV1 linear genome and circular genome and result determination

[0080] In this example, a detection method and result determination of real-time fluorescence quantitative PCR using the kit assembled in Example 1 are disclosed, as follows.

[0081] 1. Genome extraction

[0082] Collect throat swabs, nasal swabs, nasopharyngeal swabs, sputum, or bronchoalveolar lavage fluid samples and extract DNA using commercial kits.

[0083] 2. Preparation of the dual PCR reaction system for HBoV circular genome and internal reference gene RNP

[0084] The 20 μL duplex PCR reaction system is configured as follows:

[0085] DNA template 5 μL;

[0086] Hot Start DNA Polymerase (5U / μL) 0.2μL;

[0087] 10× PCR buffer 2 μL;

[0088] UDG (2U / μL) 0.1μL;

[0089] dN(U)TP (25 mM) 0.16 μL;

[0090] MgCl2 (25 mM) 2.4 μL;

[0091] 10× primer-probe mixture 2 μL;

[0092] Add ultrapure water to 20 μL.

[0093] The primers and probes for the HBoV circular genome and the internal reference gene are the primers and probes shown in Table 1 in Example 1; in the above reaction system, the total concentration of all primers is 8 μM, and the total concentration of all probes is 4 μM.

[0094] 3. PCR reaction

[0095] Place the PCR tube into a fluorescent quantitative PCR instrument and perform the PCR reaction according to the following program: 50°C, 2 min; 94°C, 5 min; 94°C, 5 s, 60°C, 30 s, and cycle 45 reactions.

[0096] The specific determination method of the results is shown in Table 2.

[0097] Table 2. HBoV circular genome detection result judgment table

[0098] .

[0099] As shown in Table 2, when the RNP channel detection result is positive, if there is no signal in the FAM channel, it indicates that the test sample does not contain the HBoV circular genome; if there is a signal in the FAM channel, it indicates that the test sample contains the HBoV circular genome.

[0100] Example 3: Minimum detection limit of HBoV1 circular genome

[0101] In this example, the minimum detection limit of the kit assembled in Example 1 for HBoV1 circular genome was tested.

[0102] Through molecular cloning technology, the full-length HBoV1 circular genome was constructed into the high-copy vector pGem T vector (purchased from Promega (Beijing) Biotechnology Co., Ltd., catalog number A3600). The full-length circular genome includes the full-length linear genome and the circularization site portion, wherein the circularization site portion includes the binding site of the circular genome primer; the linear genome portion of the full-length circular genome was obtained from a HBoV1-positive clinical sample by segmented PCR amplification, and the circularization site portion of the circular genome was obtained from the above clinical sample by nested PCR amplification and TA cloning; the full length of the circular genome is 5298bp.

[0103] The recombinant high copy plasmid was used as a DNA template and the DNA template was gradiently diluted to 10 7 copies / mL,10 6 copies / mL,10 5 copies / mL,10 4 copies / mL,10 3 copies / mL,10 2 copies / mL,10 1 copies / mL.

[0104] Using the kit assembled in Example 1 and the detection method described in Example 2, the above DNA templates of different dilutions were subjected to real-time fluorescence quantitative PCR detection to obtain the minimum detection limit of the kit for HBoV1 circular genome. The results are shown in Table 3.

[0105] Table 3. Results of minimum detection limit test of plasmid template

[0106] .

[0107] As shown in Table 3, the minimum detection limit of the kit assembled in Example 1 for HBoV1 circular genome reached 10 3 copies / mL.

[0108] Example 4: Shelf life of the kit

[0109] The kit assembled in Example 1 was stored at -20°C and the shelf life test was performed on days 0, 10, 15, 30, 60, 90, 120, 150, 180 and 360, respectively. 5 The plasmid template containing the HBoV circular genome at 100 copies / mL was used as the test sample for evaluation. The test results of the shelf life are shown in Table 4:

[0110] Table 4. Shelf life test results

[0111] Shelf life Validation of testing target genomes Day 0 efficient Day 10 efficient Day 15 efficient Day 30 efficient Day 60 efficient Day 90 efficient Day 120 efficient Day 150 efficient Day 180 efficient Day 360 efficient .

[0112] As shown in Table 4, the test kit stored in a -20°C refrigerator is effective in detecting the target genome at different storage periods. The experimental results show that the shelf life of the test kit is at least 12 months.

[0113] Example 5: Detection specificity of the kit

[0114] In this example, the detection specificity of the kit of the present invention was evaluated by testing the detection effect of the kit of the present invention on a series of unrelated pathogens.

[0115] The unrelated pathogens selected included human coronavirus, influenza virus, adenovirus, rhinovirus, parainfluenza virus, respiratory syncytial virus, cytomegalovirus, measles virus, human metapneumovirus, mumps virus, Chlamydia pneumoniae, Mycoplasma pneumoniae, Haemophilus influenzae, Neisseria meningitidis, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus salivarius, Escherichia coli, Lactobacillus, Moraxella catarrhalis, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Staphylococcus epidermidis, which have sequence homology with the target pathogen (i.e., HBoV1), are likely to cause the same or similar clinical symptoms, and the sampling sites are prone to concurrent infection.

[0116] Clinical samples positive for pathogens such as human coronavirus, influenza virus, adenovirus, rhinovirus, parainfluenza virus, respiratory syncytial virus, cytomegalovirus, measles virus, human metapneumovirus, mumps virus, Chlamydia pneumoniae, Mycoplasma pneumoniae, Haemophilus influenzae, Neisseria meningitidis, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus salivarius, Escherichia coli, Lactobacillus, Moraxella catarrhalis, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Staphylococcus epidermidis were used to detect pathogens using the kit assembled in Example 1, and the test results are shown in Table 5 below.

[0117] Table 5. Real-time fluorescence quantitative PCR amplification results of the kit of the present invention for detecting unrelated pathogens

[0118] Sample Type FAM channel (circular genome) ROX channel (reference gene RNP) Human coronavirus NA 30.415 Influenza virus NA 26.807 Adenovirus NA 25.336 Rhinovirus NA 22.234 Parainfluenza virus NA 25.878 Respiratory syncytial virus NA 22.591 Cytomegalovirus NA 26.619 Measles virus NA 24.790 Human metapneumovirus NA 23.839 Mumps virus NA 24.278 Chlamydia pneumoniae NA 25.931 Mycoplasma pneumoniae NA 27.363 Haemophilus influenzae NA 25.541 Neisseria meningitidis NA 29.044 Staphylococcus aureus NA 22.568 Streptococcus pneumoniae NA 24.583 Streptococcus pyogenes NA 28.781 Streptococcus salivarius NA 26.378 Escherichia coli NA 23.465 Lactobacillus NA 29.672 Moraxella catarrhalis NA 25.374 Gonorrhea NA 25.578 Pseudomonas aeruginosa NA 26.499 Staphylococcus epidermidis NA 22.149 .

[0119] In Table 5, NA means that the CT value was not detected.

[0120] Table 5 shows that the detection result of the internal reference gene is positive, proving that the detection system is established; and for the detection of each microorganism to be tested, no corresponding fluorescence signal appeared in the detection channel for the HBoV1 circular genome, indicating that: the kit can effectively distinguish non-targets and has good specificity.

[0121] Example 6: Establishment of the standard curve of the kit and its detection reliability

[0122] The recombinant high-copy plasmid constructed in Example 3 was selected as a template, and the template was gradiently diluted to 10 8 copies / mL,10 7 copies / mL,10 6 copies / mL,10 5 copies / mL,10 4 The kit assembled in Example 1 was used to detect templates of different dilutions, and the test results of the standard curve of the kit were shown in Table 6:

[0123] Table 6. Results of the HBoV1 circular genome standard curve test

[0124] .

[0125] As shown in Table 6, the kit 4 -10 8 When the plasmid containing the HBoV circular genome was tested at 100 copies / mL, the linear correlation coefficient was greater than 0.99, indicating that the linear correlation was good and the test results were relatively reliable.

[0126] Example 7: Detection Example of Kit

[0127] HBoV1-positive clinical samples detected by the 13 respiratory pathogens multiplex detection kit (PCR capillary electrophoresis fragment analysis method) of Haiershi Gene Technology Co., Ltd. were selected, and the HBoV1 circular genome head-tail sequence of the HBoV1-positive specimens was amplified by nested PCR, wherein the primers used in the nested PCR were designed based on the non-coding region sequence of HBoV1 (JQ923422), and the primer sequences are shown in Table 7; wherein, the outer primers of the first round of PCR were HBoV-F1-Tail(+) and HBoV-1-R1-Head(-), and the inner primers of the second round of PCR were HBoV-1-F2-Tail(+) and HBoV-1-R2-Head(-). These primers were synthesized by Shanghai Invitrogen Biotechnology Co., Ltd. and purified by PAGE.

[0128] Table 7. Primers used in nested PCR

[0129] .

[0130] The clinical samples with negative HBoV1 circular genome test results and the clinical samples with positive HBoV1 circular genome test results were respectively subjected to real-time fluorescence quantitative PCR test using the kit of the present invention, and the results are shown in Table 8 and Table 9, respectively.

[0131] Table 8. Detection results of the kit of the present invention for clinical samples that were positive for HBoV1 linear genome and negative for circular genome by nested PCR

[0132] Sample Type FAM channel (circular genome) ROX channel (reference gene RNP) HBoV1 line positive ring negative 1 NA 26.632 HBoV1 line positive ring negative 2 NA 27.364 HBoV1 line positive ring negative 3 NA 21.607 HBoV1 line positive ring negative 4 NA 25.680 HBoV1 line positive ring negative 5 NA 29.052 HBoV1 line positive ring negative 6 NA 24.108 HBoV1 line positive ring negative 7 NA 27.125 HBoV1 line positive ring negative 8 NA 25.661 .

[0133] In Table 8, NA means that the CT value was not detected.

[0134] Table 9. Detection results of the kit of the present invention for clinical samples that were positive for HBoV1 linear genome and positive for circular genome by nested PCR

[0135] Sample Type FAM channel (circular genome) ROX channel (reference gene RNP) HBoV1 line positive ring positive 1 35.237 26.632 HBoV1 line positive ring positive 2 32.811 27.364 HBoV1 line positive ring positive 3 30.832 21.607 HBoV1 line positive ring positive 4 34.876 25.680 HBoV1 line positive ring positive 5 33.270 29.052 HBoV1 line positive ring positive 6 34.791 24.108 HBoV1 line Yanghuan Yang7 31.760 27.125 HBoV1 line positive ring positive 8 35.914 25.661 .

[0136] The above results show that the detection results of the kit of the present invention for HBoV1 circular genome are completely consistent with the nested PCR detection results. It is known in the art that nested PCR detection is the gold standard for HBoV1 circular genome detection. Therefore, it can be seen that the kit of the present invention can effectively and accurately detect HBoV1 circular genome in clinical samples.

[0137] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A nucleic acid composition for detecting the circular genome of human bocavirus type 1, It is characterized in that The nucleic acid composition comprises: A primer pair and a probe for specifically amplifying the human bocavirus circular genome, the primer pair comprising: an upstream primer HBoV-CF having a nucleotide sequence as shown in SEQ ID NO:1, and a downstream primer HBoV-CR having a nucleotide sequence as shown in SEQ ID NO:2, and the probe is a probe HBoV-CP having a nucleotide sequence as shown in SEQ ID NO:

3.

2. The nucleic acid composition according to claim 1, It is characterized in that The 5' end of the probe HBoV-CP is labeled with a fluorescent reporter group, and the 3' end thereof is labeled with a fluorescent quencher group.

3. The nucleic acid composition according to claim 2, It is characterized in that The fluorescent reporter group is selected from: FAM, Cy5, VIC, JOE, TET, HEX, Cy3 and ROX; And / or, the fluorescence quenching group is selected from: TAMRA, BHQ1 and BHQ2.

4. The nucleic acid composition according to any one of claims 1 to 3, It is characterized in that The nucleic acid composition also includes a detection system for detecting an internal reference gene.

5. The nucleic acid composition according to claim 4, It is characterized in that The internal reference gene is the ribonuclease P gene, and the detection system for detecting the ribonuclease P gene includes: The upstream primer RNP-F having a nucleotide sequence as shown in SEQ ID NO:4; A downstream primer RNP-R having a nucleotide sequence as shown in SEQ ID NO:5; and, Optionally, the nucleotide sequence of the probe RNP-P is as shown in SEQ ID NO:

6.

6. The nucleic acid composition according to claim 5, It is characterized in that The 5' end of the probe RNP-P is labeled with a fluorescent reporter group, which is selected from FAM, Cy5, VIC, JOE, TET, HEX, Cy3 and ROX, and is different from the fluorescent reporter group at the 5' end of the probe HBoV-CP; and the 3' end of the probe RNP-P is labeled with a fluorescent quencher group, which is selected from: TAMRA, BHQ1 and BHQ2.

7. Use of the nucleic acid composition according to any one of claims 1 to 6 in the preparation of a kit for detecting human bocavirus type 1.

8. A kit for detecting human bocavirus type 1, comprising the nucleic acid composition according to any one of claims 1 to 6.

9. A method for detecting human bocavirus type 1 for non-disease diagnosis purposes, It is characterized in that Using the DNA of the sample to be tested as a template, PCR amplification is performed using the nucleic acid composition according to any one of claims 1 to 6 or the kit according to claim 8, and judging whether the sample to be tested contains the human bocavirus type 1 circular genome according to the amplification curve.